This activity is designed to meet the educational needs of physicians, nurses, and advanced practice clinicians who manage patients with multiple sclerosis (MS).
In MS management, the concepts of NEDA for “no evidence of disease activity” and MEDA for “minimal evidence of disease activity” have emerged in an attempt to define treatment goals and clinical trial outcomes. NEDA and MEDA are controversial, since much underlying disease activity may occur below the threshold of clinical detection and current treatments do not guarantee NEDA. What is a realistic goal in today’s environment, and what level of change is considered “acceptable” before a therapeutic switch is considered? And importantly, how do we discuss NEDA with patients? This Webinar explores these questions with MS expert faculty members Robert Naismith and Amy Perrin Ross, who have discussed and debated these concepts at international conferences.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center
Robert Naismith, MD
Director, John L. Trotter MS Clinic
Director, Multiple Sclerosis Clinical Trials Program
St Louis, MO
Accreditation and Credit Statements
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The CMSC designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CMSC designates this enduring material for 1.0 contact hour (1.0 in the area of pharmacology).
This activity is supported by an educational grant from Genentech.
Release date: 12/5/18. Valid for credit through: 12/4/19